[Clinical researchers and pharmaceutical industry. The examples of troglitazone and mibefradil].
A newly introduced drug may find many obstacles in its path. The intensity of marketing of new drugs can have unwanted effects. When new drugs are prescribed for a population that differs widely from that in clinical trials, unforeseen side effects can occur. The examples of troglitazone and mibefradil illustrate these mechanisms. It is the responsibility of the drug manufacturers and prescribers to let new drugs gradually find their therapeutic position. Otherwise exaggeration of untoward effects may lead to the speedy and possibly premature withdrawal of the drugs.
Bouvy
M L
ML
SIR Institute for Pharmacy Practice Research, Theda Mansholtstraat, Leiden.
Egberts
A C
AC
Leufkens
H G
HG
D000959:Antihypertensive Agents / Q000494:pharmacology*; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D002839:Chromans / Q000494:pharmacology*; D017277:Drug Approval / Q000379:methods*; D004345:Drug Industry / Q000639:trends*; D004335:Drug and Narcotic Control / Q000379:methods*; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D020748:Mibefradil / Q000494:pharmacology*; D009426:Netherlands; D011358:Product Surveillance, Postmarketing; D013844:Thiazoles / Q000494:pharmacology*; D045162:Thiazolidinediones; D000077288:Troglitazone; D014481:United States
D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D002839:Chromans; D007004:Hypoglycemic Agents; D013844:Thiazoles; D045162:Thiazolidinediones; D020748:Mibefradil; D000077288:Troglitazone